Atea Pharmaceuticals, Inc. Capital Expenditures
Atea Pharmaceuticals, Inc. (AVIR) reported Capital Expenditures of $1.94 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-02-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2024-02-28
- Atea Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2022-12-31 was $0.00.
- Atea Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2022-09-30 was $20.00K.
- Atea Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2022-06-30 was $1.88M.
- Atea Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2022-03-31 was $44.00K.
- Atea Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $1.94M, a 48475.00% increase from fiscal 2021.
- Atea Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2021 was $4.00K, a 84.62% decline from fiscal 2020.
- Atea Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2020 was $26.00K, a 1200.00% increase from fiscal 2019.
- Atea Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2019 was $2.00K, a 83.33% decline from fiscal 2018.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $20.00K derived: sum of 2 quarters · filed 2024-02-28 | $1.90M derived: sum of 3 quarters · filed 2024-02-28 | $1.94M 10-K · filed 2024-02-28 |
| 2022-09-30 | $20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.90M derived: sum of 2 quarters · filed 2023-11-08 | $1.94M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.92M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $44.00K 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $4.00K 10-K · filed 2023-02-28 | |||
| 2020-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $20.00K derived: sum of 2 quarters · filed 2023-02-28 | $26.00K 10-K · filed 2023-02-28 | |
| 2020-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $21.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $6.00K 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.00K 10-K · filed 2022-02-28 | ||
| 2019-09-30 | $2.00K 10-Q · filed 2020-12-10 | |||
| 2018-12-31 | $12.00K 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |